Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ya-Nan Wang, Zhi-Qiang Cai, Chen-Kang Zhao, Bo-Wang, Liang-Liang Chi, Wei-Tao Qin, Li-Hua Wu & De-Qiang Zheng. (2023) Novel 4-arylaminoquinazoline derivatives: design, synthesis, crystal structure and biological evaluation as potent antitumor agents. Molecular Crystals and Liquid Crystals 759:1, pages 80-98.
Read now
Read now
Meng-Jie Li, Jun Wei, Guo-Ping Ai, Ying Liu & Jian Zhu. (2022) Cancer Metastases from Lung Adenocarcinoma Disappeared After Molecular Targeted Therapy: A Successfully Clinical Treatment Experience. Pharmacogenomics and Personalized Medicine 15, pages 539-546.
Read now
Read now
Qi Zhang & Yi-Long Wu. (2016) Safety and efficacy of targeted agents monotherapy in advanced NSCLC. Expert Review of Clinical Pharmacology 9:1, pages 143-155.
Read now
Read now
Articles from other publishers (16)
Qi Zhou, Feng Ye, Zhize Ye, Nanyong Gao, Qihui Kong, Xiaoqin Hu, Jianchang Qian & Bin Wu. (2023) The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism. PeerJ 11, pages e16601.
Crossref
Crossref
Bo Li, Wenqian Chen, Fang Liu, Xiaoxue Wang, Wei Qin, Shu Li, Hongkai Lu, Guan Wang, Xiaoyang Liu, Pengmei Li, Xianbo Zuo, Xianglin Zhang, Lihong Liu & Meng Yang. (2023) A fully validated method for simultaneous determination of icotinib, osimertinib, gefitinib and O-desmethyl gefitinib in human plasma using UPLC-MS/MS for therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis 236, pages 115697.
Crossref
Crossref
E.J. Corey & Yong‐Jin Wu. 2023. Molecules Engineered Against Oncogenic Proteins and Cancer. Molecules Engineered Against Oncogenic Proteins and Cancer
59
96
.
Robert Roskoski Jr.. (2023) Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States. Pharmacological Research 194, pages 106847.
Crossref
Crossref
Poojarani Panda, Henu Kumar Verma & Lakkakula V. K. S. Bhaskar. (2023) Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies. Onco 3:3, pages 127-146.
Crossref
Crossref
Junhong Ye, Jifu Li & Ping Zhao. (2023) The Silkworm Carboxypeptidase Inhibitor Prevents Gastric Cancer Cells’ Proliferation through the EGF/EGFR Signaling Pathway. International Journal of Molecular Sciences 24:2, pages 1078.
Crossref
Crossref
Yuankai Shi. (2023) Landscape of the clinical development of China innovative anti-lung cancer drugs. Cancer Pathogenesis and Therapy 1:1, pages 67-75.
Crossref
Crossref
子繁 王. (2022) Study on First-Generation TKIs in the Treatment of Patients with Unresectable EGFR-Mutation-Positive Non-Small-Cell Lung Cancer. Advances in Clinical Medicine 12:02, pages 761-770.
Crossref
Crossref
Xueli Tian, Tingxuan Gu, Mee-Hyun Lee & Zigang Dong. (2022) Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:1, pages 188645.
Crossref
Crossref
Hui-Ying Li, Yu Xie, Ting-Ting Yu, Yong-Juan Lin & Zhen-Yu Yin. (2020)
Durable response to pulsatile icotinib for central nervous system metastases from
EGFR
-mutated non-small cell lung cancer: A case report
. World Journal of Clinical Cases 8:2, pages 370-376.
Crossref
Crossref
Ka Wu, Chao Guo & Rong Li. (2019) Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations. Medicine 98:18, pages e15489.
Crossref
Crossref
Ning-Ning Yang, Fei Xiong, Qing He & Yong-Song Guan. (2018) Achievable complete remission of advanced non-small-cell lung cancer: Case report and review of the literature. World Journal of Clinical Cases 6:7, pages 150-155.
Crossref
Crossref
Pinghui Xia, Jinlin Cao, Xiayi Lv, Luming Wang, Wang Lv & Jian Hu. (2018) Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation. Thoracic Cancer 9:5, pages 656-661.
Crossref
Crossref
Ning Tang, Qianqian Zhang, Shu Fang, Xiao Han & Zhehai Wang. (2016) Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts. Oncotarget 8:6, pages 9134-9143.
Crossref
Crossref
XiaoMei Zhuang, TianHong Zhang, SiJia Yue, Juan Wang, Huan Luo, YunXia Zhang, Zheng Li, JinJing Che, HaiYing Yang, Hua Li, MingShe Zhu & Chuang Lu. (2016) Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib – Enhancement by ketoconazole. Biochemical Pharmacology 121, pages 67-77.
Crossref
Crossref
Jing Zhao, Hong Shen, Han-Guang Hu & Jian-Jin Huang. (2015) Icotinib plus gemcitabine for metastatic pancreatic cancer: A case report. World Journal of Gastroenterology 21:11, pages 3441-3446.
Crossref
Crossref